Glucose-6-phosphate isomerase (GPI) deficiency cause hereditary nonspherocytic hemolytic anemia (HNSHA) of variable severity in individuals homozygous or compound heterozygous for mutations in GPI gene. This work presents clinical features and genotypic results of two patients of Portuguese origin with GPI deficiency. The patients suffer from a mild hemolytic anemia (Hb levels ranging from 10 to 12.7 g/mL) associated with macrocitosis, reticulocytosis, hyperbilirubinemia, hyperferritinemia and slight splenomegaly. Genomic DNA sequencing revealed in one patient homozygosity for a new missense mutation in exon 3, c.260G>C (p.Gly87Ala), and in the second patient compound heterozygosity for the same missense mutation (p.Gly87Ala), along with a frameshift mutation resulting from a single nucleotide deletion in exon 14, c.1238delA (p.Gln413Arg fs*24). Mutation p.Gln413Arg fs*24 is the first frameshift null mutation to be described in GPI deficiency. Molecular modeling suggests that the structural change induced by the p.Gly87Ala pathogenic variant has direct impact in the structural arrangement of the region close to the active site of the enzyme.
Introduction
Glucose-6-phosphate isomerase (GPI, EC 5.3.1.9) is a homodimeric enzyme that catalyses the interconversion of glucose-6-phosphate (G6P) and fructose-6-phosphate (F6P), in the second reaction step of the Embden-Meyerhof glycolytic pathway [1] .
The enzyme is present ubiquitously in most organisms and expressed in all tissues, which has several physiological consequences in addition to its essential role in carbohydrate metabolism. GPI belongs to the moonlighting family of proteins having multiple functions/activities [2] . Molecular cloning and sequencing revealed that GPI share the same sequence to the protein known as neuroleukin (NLK), a neurotrophic factor that mediates differentiation and survival of embryonic spinal and sensory neurons [3, 4] . GPI has been shown to work as autocrine motility factor (AMF), a tumor-secreted cytokine which stimulates cell migration and metastasis in an autocrine manner in various tumor cells [5] [6] [7] . GPI also shares sequence homology with the differentiation and maturation inducer for human myeloid leukemia HL-60 cells to terminal monocytic cells which indicates that GPI and maturation factor (MF) also share a common biological function, regulating differentiation and proliferation of human myeloid leukemic cells [2, 8] . It was also found that chronic arthritis spontaneously developed by the K/BxN T cell receptor-transgenic mouse, with many features of human rheumatoid arthritis disease, is initiated by T cell recognition of GPI enzyme [9] . Moreover, immunization with human recombinant GPI protein induced arthritis in several mice models [10] [11] [12] . Recent literature also suggests a positive correlation between anti-GPI autoantibody and the arthritis disease in humans [13] .
GPI deficiency (OMIM: 172400) is the second most frequent erythroenzymopathy in glycolysis and since the first report of the disease [14] about fifty cases have been reported throughout the world [1, 15] . Deficiency of the enzymatic activity occurs in individuals homozygous or compound heterozygous for GPI gene mutations and affects mostly erythrocytes causing hereditary nonspherocytic hemolytic anemia (HNSHA).
Diagnosis is based on determination of the GPI activity in the red blood cells by enzyme quantitative assay. The major clinical features include variable degrees of jaundice, slight-to-moderate splenomegaly, an increased incidence of gallstones, and mild to severe anemia that is normochromic in most of the cases [1] . In severe cases GPI deficiency was associated with hydrops fetalis and neonatal death [16] . Few patients present with neuromuscular dysfunctions defined by muscle weakness and mental retardation [17] .
The gene encoding GPI is located on chromosome 19q13.1 [18] , contains 18 exons [19] , and the cDNA of 1.9 kb translates a protein of 558 amino acids. The molecular characterization of GPI deficient variants shows that the gene defects are mostly missense mutations leading to protein instability or negatively influence the enzyme catalytic activity [1, 15] . Until now 34 GPI pathogenic variants have been documented [1, 20, 21] (HGMD, http://www.biobase-international.com), including 28 missense, three nonsense, two splicing and one recently described frameshift mutation (submitted).
A Portuguese GPI deficient patient was previously reported with hemolytic anemia associated with hyperbilirubinemia and splenomegaly, showing severe neurological impairment [22] , however, at that time, molecular analysis could not be performed. In this work we present the clinical features and genotypic analysis of two additional unrelated Portuguese patients with GPI deficiency. μmol/L). GPI activity was 5 IU/g Hb (control 49 IU/g Hb). PK activity was 10 IU/g Hb (control 5.3 IU/g Hb) and G6PD activity was 11.2 IU/g Hb (control 9.4 IU/g Hb). His medical history included a total splenectomy after splenic injury at age of 18-year-old.
Methods

Patients
Hematological and biochemical analysis
Routine hematological studies were conducted with standard methods [23] . Red cell enzyme activities, expressed as IU/g Hb, were measured in hemolysates according to the methods recommended by the International Committee for Standardization in
Haematology [24] .
Genetic analysis
Genomic DNA was extracted from peripheral blood leukocytes of both patients and their relatives using standard methods. Polymerase chain reaction (PCR) to amplify GPI exons and adjacent intronic regions was performed with primers and conditions reported in
Beutler et al. [25] . PCR products were purified with a ExoSap IT (Valencia, CA, USA)
following the manufacturer's instructions and sequenced using the ABI Prism 
Structural Modelling
To better understand the structural implications of a novel missense mutation identified in the human GPI protein, we have used Modeller 9v15 [26] to build a three-dimensional model of the mutant protein. The model was generated based on the crystallographic structure of the human GPI with pdb code: 1NUH [27] . During the homology modelling process, Modeller starts by creating a single point mutation in the original structure and ends by optimizing and refining the mutant side-chain by conjugated gradient and simple Molecular Dynamics simulation [28] . In the end, PROCHECK [29] was used to perform a full stereochemical validation of the generated model.
Computational (in silico) predictive programs
The probable phenotypic effect of amino acid change for the new missense mutation was evaluated by using in silico tools commonly used for missense variant interpretation, 
Results
The hematological, biochemical and molecular findings of the two unrelated Portuguese patients with GPI deficiency are summarized in Table 1 . The two patients suffer from a mild hemolytic anemia (with Hb levels ranging from 10 to 12.7 g/mL) associated with macrocytosis, reticulocytosis, slight splenomegaly, hyperbilirubinemia and hyperferritinemia. The diagnosis of GPI deficiency was made after exclusion of the most common causes of hemolytic anemia and by the demonstration of a reduced GPI enzyme activity (about 80% in patient 1 and 90% in patient 2). Moreover, the new variant was not found in ExAC, 1000Genomes or HGMD.
Structure analysis of the human GPI protein evidenced that Glycine 87 is placed at the end of α-helice 7 (composed by residues 76-86), preceding a loop region where Glutamate 93 and Arginine 95 are found (see Figure 1 ). Both these two residues are in close proximity with the active site of the GPI protein and heavily contributing to the stabilizing hydrogen bond network found in this region of the protein. Glycine residues, due to their stereochemical properties, are commonly found at the end and beginning of helical regions in proteins. Therefore, an Alanine mutant of a Glycine residue in such regions is expected to perturb neighbor regions of the protein. In GPI, due to the proximity of Glycine 87 to the binding and active site of the GPI protein, one can propose that when mutated, the activity of the enzyme is affected. In fact, these observations corroborate the experimental data previously described for patient 1 where it is clear that a reduction in GPI activity is observed when this mutation is present. Moreover, the bioinformatic analysis using in silico tools to predict whether the new missense change p.Gly87Ala is damaging to the resultant protein function showed the following outputs (score / prediction): PolyPhen-2 0.856 / possibly damaging; MutationAssessor 3.595 / high impact; PROVEAN -4.55 / deleterious; SIFT 0.035 / damaging; MutationTaster 0.999 / disease causing; MutPred: probability of being deleterious 0.938.
Discussion
In two unrelated patients with chronic hemolytic anemia associated to GPI deficiency, two different mutations were identified: one novel missense mutation, c.260G>C
(p.Gly87Ala), and one frameshift mutation due to a single nucleotide deletion, c.1238delA (p.Gln413Arg fs*24). Patient 1 is homozygous for mutation p.Gly87Ala, and the second patient is compound heterozygous for this same missense mutation (p.Gly87Ala) along with the frameshift variant c.1238delA (p.Gln413Arg fs*24).
The fact that mutation p.Gly87Ala was found in two unrelated patients, at the homozygous state in a non-consanguineous patient (which means, three mutated alleles in four unrelated chromosomes), would suggest the likelihood of a higher prevalence of this mutated allele among the Portuguese population. However, the study of 50 subjects from the general Portuguese population revealing no abnormal c.260C alleles did not enable to reach that conclusion.
Despite the severe reduction in GPI activity in red cells (about 80% and 90%), the nature of the anemia in both patients is mild (hemoglobin 10-12 g/dL). This finding is not in disagreement with previous reports, since genotype-phenotype correlations are difficult to establish in GPI deficiency. It is known that, in some patients, the degree of the GPI deficiency is not directed correlated with the severity of the anemia: patients with about half GPI activity display severe anemia while others with about 10% residual activity present with a mild to moderate anemia [1] . Moreover, patients with the same genotype and similar GPI activity reduction may have anemia of different severity [1] .
The structural analysis of the mutant model of the GPI protein suggests that the p.Gly87Ala mutation has direct impact in the structural arrangement of the region close to the active site. Mutation p.Gly87Ala seems, not only to affect the stability of the α- Mutation c.1238delA (p.Gln413Arg fs*24) is the first frameshift null mutation to be described in GPI deficiency. The heterozygous state condition for all these null mutations reflects GPI as an essential housekeeping enzyme.
Neurological symptoms were not found in these two Portuguese patients, which
indicate that the neurothrophic activity of the GPI enzyme was not affected by the aminoacid substitution p.Gly87Ala. Previously, a Portuguese patient was reported to
show severe neuromuscular impairment [22] . However, this GPI variant was not characterized at the molecular level and a sample is currently unavailable. It remains unexplained why some GPI mutations cause neurological symptomatology and others do not. From all patients reported with enzymatic deficiency in GPI, neurologic impairment was observed in at least five [1] . Until now, only two patients (GPI variants Homburg and Mount Scopus) with neurological symptoms have been characterized at the molecular level [1] . Patient GPI Homburg is compound heterozygous for two missense mutations, p.His20Pro and p.Leu339Pro, that are likely to affect the folding and activity of the enzyme [17, 36] . Based on this case, where the neuromuscular symptoms were directly related to the enzyme deficiency, the authors proposed GPI mutations that lead to incorrect folding destroys both catalytic and neurotrophic (NLK) activities of GPI protein; those alterations at the active site, or at or close to the subunit interface that destabilize the dimer but not necessarily the monomer, allow a correct folding retaining the neurotrophic properties of the molecule [17] . In concordance with this hypothesis, molecular modelling suggest that the GPI missense mutation p.Gly87Ala identified in the two Portuguese patients exhibiting no neurological symptoms has direct impact in the region close to the active site. Similarly, previous reported patients carrying mutations at or close to the active site, including H389R [17] , R273H [37] , and S278L [37] did not show neurological impairment.
In conclusion, this report describes the clinical features and the molecular etiology of two GPI deficient Portuguese patients. We found one patient homozygous for the novel GPI missense mutation c.260G>C (p.Gly87Ala) and a second patient compound heterozygous for p.Gly87Ala and the frameshift p.Gln413Arg fs*24. Molecular modeling suggests that the structural changes induced by the p.Gly87Ala mutation affects the active site of the enzyme. Both patients showed no neurological impairment. Table 2 . Mutations reported until now in patients with GPI deficiency.
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